If Australia followed England’s lead and listed drugs such as Wegovy on the PBS for weight loss, this could bring the cost ...
Vitamin D deficiency (VDD) is independently associated with increased depression risk in patients with chronic kidney disease ...
There is a dose-response relationship between physical activity and rapid kidney function decline in older adults, according ...
Novo Nordisk alleges Singaporean biotech KBP Biosciences made misleading statements before the two firms inked a licensing ...
The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...
Biosimilars have also made inroads among generic suppliers. But development is lengthy and expensive. McKinsey estimates that it costs $100 to $300 million to develop a biosimilar and that it takes ...
A lawsuit filed in the Singapore International Commercial Court is seeking $830 million in damages from KBP, with Novo ...
Five regions in the U.S. have been selected to implement a new preventive health initiative to improve care for people with a cluster of chronic ... Cardiovascular-Kidney-Metabolic Health Initiative, ...
After its potential kidney disease drug went down in flames late last year, Novo Nordisk is pinning the blame on alleged ...
American Heart Association initiative aims to improve care for people in Atlanta; Baton Rouge, La.; Washington, D.C.; Maryland; San Diego and Ohio who have a cluster of conditions called cardiovascula ...